QNCX — QUINCE THERAPEUTICS, INC. (Healthcare >> Biotechnology)
QNCX FAQ
What is QNCX's P/E ratio?
QUINCE THERAPEUTICS, INC. (QNCX) currently trades at a P/E ratio of 0.51.
What is QNCX's ROE?
QUINCE THERAPEUTICS, INC. reports a Return on Equity (ROE) of -210.80%.
What is QNCX's dividend yield?
QUINCE THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is QNCX's Deepscope Quality Score?
Deepscope rates QNCX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy QNCX?
Deepscope's AI Timing Score for QNCX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does QNCX belong to?
QUINCE THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.90
Price
0.00
(0.30%)
Day Change
|
|
|---|
QNCX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.90 |
| PBV / Sector |
1.16 / 4.95
GREAT
|
| Earning Per Share | -1.63 |
| PE / Sector |
0.51 / 18.38
GREAT
|
| PEG or PE/Growth / Sector |
0.04 / 0.62
GREAT
|
| Average 1M Daily Value |
0.81 M
GREAT
|
| Average 1W Daily Value |
0.26 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-17 09:51:43 |
| Symbol | QNCX |
| Name | QUINCE THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 19.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 18.21 / 9,028.40 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 415 910 5717
Website: https://quincetx.com
Sector: Healthcare >> Biotechnology
Description: Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google